Related references
Note: Only part of the references are listed.Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations
Kristopher R. Bosse et al.
CANCER (2016)
Mutational dynamics between primary and relapse neuroblastomas
Alexander Schramm et al.
NATURE GENETICS (2015)
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia
T. Yoshizato et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours
Annica Wilzen et al.
MOLECULAR CANCER (2013)
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh et al.
NATURE GENETICS (2013)
An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data
Yuichi Shiraishi et al.
NUCLEIC ACIDS RESEARCH (2013)
Promising Therapeutic Targets in Neuroblastoma
Katherine K. Matthay et al.
CLINICAL CANCER RESEARCH (2012)
ALK germline mutations in patients with neuroblastorna: a rare and weakly penetrant syndrome
Franck Bourdeaut et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2012)
Prognostic Value of SOX2 Expression in Neuroblastoma
Maria del Carmen Gomez-Mateo et al.
GENES CHROMOSOMES & CANCER (2011)
Genome-Wide Linkage Analysis to Identify Genetic Modifiers of ALK Mutation Penetrance in Familial Neuroblastoma
Marcella Devoto et al.
HUMAN HEREDITY (2011)
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Tom Monclair et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Identification of ALK as a major familial neuroblastoma predisposition gene
Yael P. Mosse et al.
NATURE (2008)
Oncogenic mutations of ALK kinase in neuroblastoma
Yuyan Chen et al.
NATURE (2008)
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Isabelle Janoueix-Lerosey et al.
NATURE (2008)
Chromosome 1p and 11q deletions and outcome in neuroblastoma
EF Attiyeh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma:: A Pediatric Oncology Group Study
RE George et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
